Reactive vs. Proactive Pain Control in IBD (PAIN-Sparing)
Inflammatory Bowel Diseases, Pain, Opioid Use
About this trial
This is an interventional health services research trial for Inflammatory Bowel Diseases focused on measuring Pain, Inflammatory Bowel Disease, Opioids
Eligibility Criteria
Inclusion Criteria:
- Adults with confirmed IBD diagnosis
- Admitted for primary IBD-related sign or symptom
Exclusion Criteria:
- Admitted for primary non-IBD complaint
- Surgery in the last 30 days
- Alternative (non-IBD) GI diagnosis determined
- Age <18
- Pregnancy
Sites / Locations
- Cedars-Sinai Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Proactive
Reactive (Control Group)
Proactive Analgesic Inpatient Narcotic-Sparing: Pain management in patients in the proactive physician-behavior group will be based on the IBD Pain orderset in our EMR. This orderset is already in use and standard-of-care at Cedars. The orderset uses pain medications, which have evidence for use in IBD. The orderset is simply a guide to clinicians and does not force any doctor or patient to be in a "protocol".
Pain management in patients in the reactive group (control group) will follow traditional prescribing habits. As different providers vary in the way they treat pain, analgesic medication prescribing in the control group will be inherently variable in nature. The control group does not constitute a lack of treatment or placebo; rather, pain management in the control group will not be proactive as in the intervention group.